Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.
Location: United States, New York
Employees: 51-200
Total raised: $61M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | dRx Capita... | drxcapital... |
| 28.09.2020 | McKesson V... | ventures.m... |
| 09.06.2024 | dRx Capita... | live-drxca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.02.2022 | Series C | $45M | - |
| 29.09.2020 | Series B | $16M | - |
Mentions in press and media 21
| Date | Title | Description |
| 01.09.2026 | Koneksa Announces Topline Results from KH007 Study Evaluating Digital Measures of Parkinson’s Disease Progression | Study meets primary compliance endpoint, reinforcing the value of Koneksa’s integrated measurement platform and syndicated, precompetitive study model. What makes KH007 impressive is patients are willing to carry the burden of continuous me... |
| 02.06.2026 | Koneksa Launches the First Intelligent Submission Software to Unify Clinical Submissions in One Auditable Workflow | Lodestar™ eliminates submission pipeline fragmentation through AI-assisted, auditable workflow, validated in completed LEARNS clinical study. Sponsors and CROs were spending months doing reconciliation work that the software should have bee... |
| 23.04.2026 | Koneksa Achieves Key Milestone with Database Lock for KH007 Study Evaluating Parkinson’s Disease Progression | Completion of data collection enables full analysis, with topline results expected in June 2026 As digital measures become more widely used, how those measurements are defined and applied will increasingly determine how confidently therapie... |
| 28.06.2023 | Koneksa Appoints Dave Hurry as Chief Data Officer and Dr. Larsson Omberg as EVP of Data Science | Koneksa, the evidence-based digital biomarkers company, announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science. Both executives will be joining the company’s lead... |
| 10.03.2023 | Chris Benko, co-founder and CEO of Koneksa Health, on VatorNews podcast | Koneksa Health is a company that is developing, testing, and validating digital biomarkers Vator · Interview with Chris Benko, CEO at Koneksa Health Steven Loeb speaks with Chris Benko, co-founder and CEO of Koneksa Health, a company that i... |
| 14.02.2022 | Digital health news, funding roundup in the prior week; February 14, 2022 | Amazon expanded its on-demand health solution; Medable partnered with CVS; COVID deaths passed 900k Top Health News Amazon Care, the company's on-demand healthcare solution, expanded to employees in all 50 states Digital clinical trials com... |
| 08.02.2022 | Koneksa secures $45M for digital biomarker platform | Koneksa has raised a $45 million Series C led by AyurMaya, an affiliate of Matrix Capital Management, with participation from Takeda Ventures and Velosity Capital. Koneksa's healthcare platform is designed to remotely collect and analyze pa... |
| 08.02.2022 | Koneksa Raises $45M in Series C Funding | Koneksa, a New York-based company focused on designing and validating digital biomarkers, raised $45M in Series C funding. The round was led by AyurMaya with participation from Takeda Ventures and Velosity Capital, as well as existing inves... |
| 07.02.2022 | Frontier and Spirit Airlines to take on the pandemic-induced travel hiatus with $6.6B deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Frontier Airlines announced it had agreed to purchase its low-cost rival Spirit Airlines this mor... |
| 07.02.2022 | Digital biomarker startup Koneksa scores $45M in Series C funding | Photo: Kwanchai Lerttanapunyaporn/Getty Images |
Show more